Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection

J Med Virol. 2022 Mar;94(3):1241-1245. doi: 10.1002/jmv.27445. Epub 2021 Nov 13.

Abstract

Immunocompromised patients have an increased risk of persistent COVID-19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti-SARS-CoV-2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody-resistant SARS-CoV-2 infections evolution in immunocompromised patients.

Keywords: COVID-19; SARS-CoV-2; Spike gene; bamlanivimab; convalescent plasma; immunocompromised.

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Drug Treatment*
  • COVID-19 Serotherapy
  • COVID-19* / therapy
  • Humans
  • Immunization, Passive
  • Immunocompromised Host*
  • Mutation
  • SARS-CoV-2 / genetics
  • Spike Glycoprotein, Coronavirus / genetics*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • bamlanivimab